Stockreport

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled ana [Read more]